Clinical Research

Beta-blockers do not benefit heart attack patients with a normal LVEF
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
Drones deliver AEDs for the first time in the United States
“This study represents a major step forward in how we respond to cardiac arrest in the United States,” explained Monique Starks, MD, principal investigator. “By integrating drone technology into emergency care, we’re working to close the critical gap between cardiac arrest and treatment."
Early TAVR for asymptomatic severe AS cuts costs, improves outcomes
The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.
Winning cash for taking blood pressure meds increases compliance
About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.
Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial
The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

Mario Gaudino, MD, explains why cardiac surgery trials need more diversity to better inform treatment decisions for women and minorities.

The lack of diversity in cardiac surgery trials may be harmful to patients

Mario Gaudino, MD, PhD, told Cardiovascular Business there is a major need for more women and minorities in today's clinical trials.

Video interview with Mario Gaudino on trends in cardiac surgery.

Veteran surgeon unpacks major changes in the world of cardiac surgery

Mario Gaudino, MD, PhD, spoke to Cardiovascular Business about minimally invasive procedures, the growing interest in clinical trials and other key trends in the world of cardiac surgery.

Predictive model helps identify malignancy in thyroid nodules.

Predictive model uses 6 ultrasound features to differentiate between benign and malignant thyroid nodules

Once the model is further validated, it could help guide providers in determining how to manage thyroid nodules.

Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs

Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.

Work begins on first ATTR-CM study of its kind

ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.

Philips launches clinical trial to study feasibility of ultra-low dose PCI procedures

Philips trial to test feasibility of reducing radiation during coronary interventions

The Philips Azurion interventional imaging system was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.

The Shockwave Medical M5+ new peripheral intravascular lithotripsy (IVL) catheter cuts procedures times in half and was showed for the first time at the American College of Cardiology (ACC) 2022 meeting. It is designed to break up calcium in heavily calcified arteries to avoid the need for vessel trauma caused by high pressure angioplasty.

IVL delivers significant value for women, real-world data confirm

Researchers tracked data from nearly 400 women with complex CAD who underwent treatment with Shockwave Medical's intravascular lithotripsy technology prior to PCI.

doctor patient elderly check up hospital

2 out of 5 heart failure patients are not seeing a cardiologist

Even seeing a cardiologist once per year can help these patients elevate their long-term survival. Many stay home, however, missing out on potentially life-saving guidance and/or treatment.

Clinical Research

Beta-blockers do not benefit heart attack patients with a normal LVEF

Drones deliver AEDs for the first time in the United States

Early TAVR for asymptomatic severe AS cuts costs, improves outcomes

Winning cash for taking blood pressure meds increases compliance

Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial